Menu Search
Equities

Tvardi Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
69C:FRA

Tvardi Therapeutics Inc

Actions
  • Price (EUR)2.41
  • Today's Change-0.265 / -9.93%
  • Shares traded120.00
  • 1 Year change--
  • Beta0.1576
Data delayed at least 15 minutes, as of Feb 06 2026 07:11 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

  • Revenue in USD (TTM)4.02m
  • Net income in USD-13.95m
  • Incorporated2004
  • Employees10.00
  • Location
    Tvardi Therapeutics Inc3 Sugar Creek Ctr Blvd, Ste 525SUGAR LAND 77478United StatesUSA
  • Phone+1 (713) 489-8654
  • Fax+1 (302) 636-5454
  • Websitehttps://tvarditherapeutics.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.